There are various assumptions and bias of the drug industry that underlie drug research. First, bias is seen as the panel to conduct research is selected. The panel may consist of workers of the companies or those that benefits from the companies as seen in the case of GlaxoSmithKline on Avandia (Whoriskey, 2012). The other assumption is that the effects of drugs are outweighed by the benefits the drugs to the patients. In the article, we note that the company disregards how Avandia is a risk to patient as it can lead to heart attacks (Whoriskey, 2012). The company assumes that benefits from the drug are more as compared to the harm it has on patients. As a result, the risk issues are not published in the final research. The other bias is seen as the drug companies dictate the drugs trials (Whoriskey, 2012). This is meant to eliminate any chance that may be unfavorable to the company. An addition bias is seen as companies withhold some of the primary information required for the research process (Whoriskey, 2012). Withholding of such information will affect the outcome.
I have one personal bias on drugs industry influence over research. The bias is that these companies are not involved in these researches for the benefit of consumers. However, the company’s main intention is to make a profit.
Whoriskey, P. (2012). As drug industry’s influence over research grows, so does the potential for bias. Retrieved from